About Primrose Bio
Primrose Bio is a company based in San Diego (United States) founded in 2023. Primrose Bio has raised $15 million across 1 funding round from investors including 1315 Capital. Primrose Bio operates in a competitive market with competitors including Neovacs, Fina Biosolutions, VERAXA, Yapanbio and Intravacc, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series B
Jun 17, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Primrose Bio
Unlock access to complete
Funding Insights of Primrose Bio
Primrose Bio has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series B round of $15 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Primrose Bio
Primrose Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include 1315 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Expansion and growth capital is provided by 1315 Capital to healthcare companies.
|
Locked | Locked | Locked |
Investor details for Primrose Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Primrose Bio
Investment portfolio details for Primrose Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Primrose Bio
Detailed financials for Primrose Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Primrose Bio Comparisons
Peer comparison for Primrose Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Primrose Bio
Primrose Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neovacs, Fina Biosolutions, VERAXA, Yapanbio and Intravacc, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccine manufacturing services are provided by Neovacs CDMO.
|
|
| Locked | Locked | Locked |
Biotechnology company specializing in bioconjugation services mainly for vaccine development
|
|
| Locked | Locked | Locked |
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
|
|
| Locked | Locked | Locked |
Contract manufacturing of bio-therapeutics and vaccines is provided.
|
|
| Locked | Locked | Locked |
Vaccine development services for bacterial and viral vaccines are provided.
|
Detailed competitors of Primrose Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Primrose Bio
Complete news archive for Primrose Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Primrose Bio
Primrose Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Primrose Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Primrose Bio is a funded company, having raised a total of $15M across 1 funding round to date.
Primrose Bio was founded in 2023 and is based in San Diego, United States. Operations in the biotechnology sector center on the discovery, development, and manufacturing of new molecules. Pfenex Expression Technology is utilized for complex protein expression. Services are provided to support advancements in molecular biology, with a focus on efficient production processes in the field.
Primrose Bio has 1 investor. Key investors include 1315 Capital.